This punctal plug prototype both blocks tear drainage and delivers dry-eye medication. Image courtesy of UNIVERSITY OF FLORIDA “It is estimated that 10–30% of people suffer from the condition known as ...

Completion of Facility Enables Initiation of Phase 3 Clinical Trial of Nepafenac in Patients Undergoing Cataract Surgery AUSTIN, Texas, Sept. 12, 2023 /PRNewswire/ -- Mati Therapeutics Inc. ("Mati") ...

A retrospective administrative claims analysis of treatment options for dry eye disease (DED) evaluated treatment patterns and utilization characteristics of patients receiving cyclosporine, punctal ...

AUSTIN, Texas--(BUSINESS WIRE)--Mati Therapeutics, Inc. (“Mati”) announced that its international patent portfolio now comprises 100 issued patents. Included in the portfolio is recently granted U.S.

Please provide your email address to receive an email when new articles are posted on . Miebo (perfluorohexyloctane ophthalmic solution, Bausch + Lomb), an eye drop that prevents tear evaporation, can ...

"We are very pleased to have recently announced the expansion of our Phase 1b trial of QLT091001 into patients with Retinitis Pigmentosa," said Bob Butchofsky, President and Chief Executive Officer of ...

The punctal plug delivery system is a minimally invasive drug delivery system that is being developed with a goal of enabling delivery of a variety of drugs to the eye over time through sustained ...

Dear Dr. Roach: I’m a 65-year-old female, non-smoker, with very dry eyes living in a dry climate. My eyes often burn and tear up, which I find curious, having been diagnosed with dry eyes. During the ...

AUSTIN, Texas, Sept. 12, 2023 /PRNewswire/ -- Mati Therapeutics Inc. ("Mati") announced that it has completed and now occupies a facility dedicated to manufacturing all products formulated in Mati's ...